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Hippocrates is often credited with ﬁrst recognizing that food could be responsible for adverse symptoms
and even death in some individuals, but it was not until the seminal observations by Prausnitz that the
investigation of food allergy was viewed on a more scientiﬁc basis. In the ﬁrst half of the 20th century,
there were periodic reports in the medical literature describing various food allergic reactions. In the
mid- to late- 1970's, the studies of Charles May and colleagues began to penetrate the medical world's
skepticism about the relevance of food allergy and how to diagnose it, since standard skin testing was
known to correlate poorly with clinical symptoms. With May's introduction of the double-blind placebo-
controlled oral food challenge, the study of food allergy became evidence-based and exponential strides
have been made over the past four decades in the study of basic immunopathogenic mechanisms and
natural history, and the diagnosis and management of food allergies. Today IgE- and non-IgE-mediated
food allergic disorders are well characterized and efforts to treat these allergies by various immuno-
therapeutic strategies are well under way.
Copyright © 2016, Japanese Society of Allergology. Production and hosting by Elsevier B.V. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Historical background
Although the ﬁrst account of food allergy is generally attributed
to Hippocrates, the Chinese emperors Shen Nong (~2735 BC) and
Huang Di (2698-2598 BC) provided advice in “Shi Jin-Jing” (“In-
terdictions concerning food”) for pregnant women to avoid certain
foods, e.g. shrimp, chicken and meats, and for individuals with
certain skin lesions (possibly atopic dermatitis lesions) to avoid
certain foods.1 In Hippocrates' writings (460e377 BC), he referred
to the presence of “hostile humors” (now known as IgE antibodies)
in some men that made them “suffer badly” following ingestion of
cheese.1 An often quoted line from a poem of Titus Lucretius Cato
(98e55 BC), “What is food to one, to another is rank poison,”1
strongly suggests an understanding of adverse reactions to foods
over 2000 years ago. In the 17th century case reports of food hy-
persensitivity reactions began to appear in the medical literature1;
Jean Baptiste van Helmont reported asthmatic attacks following the
ingestion of ﬁsh in Oriatrike published in 1662. Later Robert Willanety of Allergology.
rgology. Production and hosting by Elsedescribed urticaria following the ingestion of almonds, mush-
rooms, ﬁsh, crab, lobsters and mussels, and “urticaria febralis” (fatal
anaphylaxis) following ingestion of mussels and lobsters in his
Treatise on Dermatology, (a multi-volume publication; 1798e1808).
While various reports of reactions to foods appeared periodi-
cally in themedical literature, the classic experiment of Prausnitz in
1921 initiated the scientiﬁc investigation of food allergy and
established the immunologic basis of allergic reactions.2 In his
experiment, Prausnitz injected serum from a ﬁsh-allergic patient,
Kustner, and a non-allergic control subject into his own skin, and on
the following day he injected ﬁsh extract into the same areas. A
positive local reaction (PrausnitzeKustner test) proved sensitivity
could be transferred by a factor in serum (now known to be IgE
antibodies) from an allergic to a non-allergic individual. In a similar
experiment four years later, Freeman passively sensitized his
middle nasal turbinate with serum from an egg allergic patient and
demonstrated the induction of rhinitis (rhinorrhea and sneezing)
shortly after the ingestion of an egg the following day.3
Other early studies of food allergy focused on radiologic changes
associated with immediate hypersensitivity reactions in the
gastrointestinal tract. In one of the ﬁrst of these reports, hyperto-
nicity of the transverse and pelvic colon and hypotonicity of thevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
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allergy following the ingestion of wheat.4 In a later ﬂuoroscopic
study, Rowe and colleagues5 compared the effect of barium
contrast material containing food allergens with standard barium
contrast material in 12 food-allergic children. They noted pro-
longed gastric hypotonia and retention of the allergen test meal,
prominent pylorospasm, and subsequently increased or decreased
peristaltic activity of the intestines.
In a novel series of experiments over 70 years ago, Walzer and
his colleagues in New York utilized sera from food-allergic patients
to passively sensitize volunteers and demonstrate that “immuno-
logically” intact antigens can cross the gastrointestinal mucosal
barrier and disseminate rapidly throughout the body. The in-
vestigators passively sensitized skin on the arms of a large cohort of
normal adults with serum from a ﬁsh allergic patient and similarly
a large cohort of normal children with serum from an egg allergic
patient, as well as with control non-allergic serum.6,7 Twenty-four
hours later the adults and children were fed ﬁsh and eggs,
respectively, and within about 90 min, nearly 90% of the study
subjects developed a large wheal and ﬂare response at the site on
their arm sensitized with “allergic sera,” but not at the site with
“non-allergic, control sera.” Using similar passive sensitization,
colonic mucosa of patients who had previously undergone an
ileocolostomy was injected with sera from food allergic patients
and normal controls.8 Serum from the allergic patient was injected
at the distal (non-contiguous) site of the ileocolostomy opening and
24 h later the study subjects ingested the food allergen. Within
10e15 min, they developed hyperemia at the sensitized distal
colonic site followed shortly thereafter by pallor and edema, and
prolonged, copious mucus secretion and petechia at the injection
site. Walzer and his colleagues also studied the effects of stomach
acidity on food allergen uptake. They demonstrated that increased
stomach acidity and the presence of other food in the gut decreased
antigen absorption, while decreased stomach acidity, such as from
today's H2-blockers and proton pump inhibitors, and ingestion of
alcohol increased antigen absorption.9
In the late 1930's, six patients with gastrointestinal food allergy
or wheezing exacerbated by the ingestion of a food allergen and
control subjects were evaluated by gastroscopy.10 Thirty minutes
after a food allergen was placed on the gastric mucosa, patients
with gastrointestinal food allergy developed markedly hyperemic
and edematous patches with overlying thick gray mucus and
scattered petechiae at the site of allergen placement, similar to the
ﬁndings reported earlier by Walzer and colleagues in passively
sensitized intestinal mucosal sites.9 Only mild hyperemia of the
gastric mucosa was noted in patients with wheezing provoked by
food ingestion. Fifty years later a study conﬁrmed these earlier
observations in a cohort of 30 patients with gastrointestinal food
allergy, and established an IgE-mediated mechanism for these re-
actions.11 These investigators demonstrated that food-allergic pa-
tients had signiﬁcant food-speciﬁc IgE antibodies and increased
numbers of intestinal mast cells in the gastric mucosa compared to
normal controls, and signiﬁcant decreases in stainable mast cells
and tissue histamine following a positive food allergen response.
In 1912, Schloss introduced the concept of using extracted
protein from foods for scratch testing in the diagnosis of food al-
lergy,1 but by then there were already calls for curbing the growing
practice of “scratching the skin with a few food tests and putting the
patient on a weird and impracticable diet which usually accomplishes
no result…”1 In 1950, Loveless demonstrated that the patient's
history and presence of positive skin tests were often insufﬁcient to
diagnose food allergy in her report of the ﬁrst blinded, placebo-
controlled food trials in patients with milk allergy.12 In a later
report of 89 children being evaluated for milk allergy, Goldman and
colleagues recommended that the diagnosis of food allergy couldonly be established when withdrawal of the food (milk) from the
diet led to complete resolution of symptoms and three successive
challenges with the food (milk) duplicated the presenting symp-
toms.13 Due to the potential severity of reactions developing during
food challenges, this approach was not widely accepted. In the mid-
1970's, Charles May and his colleagues reported on the use of the
double-blind, placebo-controlled oral food challenge (DBPCFC),14
which has emerged as the accepted “gold standard” for the diag-
nosis of food allergy. A consensus document (Practall) attempting
to standardize the DBPCFC was published in 2012 by the American
Academy of Allergy & Immunology and the European Academy of
Allergy and Clinical Immunology.15
Even before Prausnitz's classic experiment demonstrating that a
transferable factor, i.e. IgE, was likely involved in the pathogenesis
of food allergy, physicians began experimenting with immuno-
therapeutic approaches to treat food allergy. The ﬁrst report of
successful oral immunotherapy (OIT) was published in the Lancet in
1908 and described the successful treatment of a child with egg-
induced anaphylaxis.16 A few scattered case reports followed
including a report by Keston, which provided very limited details
on a “…method as outlined above has been effective in desensitizing
about ﬁfty patients with allergic symptoms,”17 and reports by
Edwards18 and Unger19 that were equally vague on outcomes, e.g.
“Twelve of thirteen patients attempted have been successfully desen-
sitized by the oral method.”18
Recent past and present history
In the early 1980's, the landscape of food allergy was very
different from today: food allergy was less prevalent, there was
little public awareness of the problem, most clinicians were highly
skeptical of the diagnosis, and there was little active research going
on, primarily because many investigators did not consider the ﬁeld
to be “a real science.” Skin testing and food-speciﬁc serum IgE
values (radioallergosorbent tests [RASTs]) were seen as unreliable
diagnostic tools, given their poor correlation with oral food chal-
lenge (OFC) outcomes.20 Thirty-ﬁve years ago the perceived prev-
alence of food allergy in the United States was similar to what is
reported today, i.e. about 20%, but the actual prevalence then was
thought to be less than 1%21 compared to more recent estimates
today of 3.5%e5% of the general population22 and 8% of the pedi-
atric population.23 Some have referred to the increase in food al-
lergy and atopic dermatitis as the “second wave of the allergy
epidemic,”24 as suggested by the National Health Interview Survey
in the US (Fig. 1). Severe food-allergic reactions were rare 35 years
ago, but now represent the single leading cause of anaphylaxis
treated in American emergency departments, and data from the
USA and Australia indicate that there has been amarked increase in
hospitalizations due to food allergy in the past two decades, as
depicted in Figure 2.25 The reason for this rapid rise in food allergy
among industrialized countries around the world remains an open
question.26
Many of the same diagnostic tools used today to diagnose food
allergy were utilized 30 years ago, but these tools have been
reﬁned. Patient history and skin testing remain the cornerstone for
diagnosing food allergy. However, the characteristics of food
allergic disorders (Table 1) and food allergic symptoms (Table 2)
have been more precisely deﬁned, which has improved the diag-
nostic accuracy of the medical history and its utility in guiding
appropriate laboratory studies.27 Until the mid-1990's, most aller-
gists rarely utilized in vitro food-speciﬁc IgE measurements (RASTs)
in their food allergy work-up because of poor sensitivity and
speciﬁcity in identifying symptomatic food allergy.20 However,
with the advent of a quantitative in vitro assay, it was shown that
there was a direct correlation between the quantity of food-speciﬁc
Fig. 1. The percentage of children 0e17 years of age in the United States with a reported allergic condition in the past 12 months; 1997e2011. From Jackson KD et al. National Child
Health Services Data Brief #121; May 2013.
Fig. 2. Food-induced hospital anaphylaxis admissions in Australia by age group from 1994 to 2005. From WK Liew et al. J Allergy Clin Immunol 2009; 123:434e42.
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speciﬁc food.28,29 Since then, numerous studies in different patient
populations have been undertaken in an attempt to reﬁne the
diagnostic accuracy of quantitative serum food-speciﬁc IgE mea-
surements.30,31 More recently, the advent of quantitative IgE mea-
surements tomajor allergenic proteins within certain foods, e.g. Ara
h 2 in peanut32,33 and Cor a 9 and 14 in hazelnut,34,35 has further
improved the diagnostic accuracy of in vitro testing. In the mid-
1970's, May and Bock reported that prick skin test wheal diameters
less than 3 mm greater than the negative control were unlikely to
indicate symptomatic IgE-mediated food allergy and that OFCs
were necessary in patients with larger wheal diameters in order to
establish symptomatic food allergy.14,36 However, in 2000, Sporik
and colleagues reported that analogous to results with food-
speciﬁc IgE values, the larger the prick skin test wheal diameter,
the greater the likelihood that a patient would experience allergic
symptoms to a food and suggested wheal diameter cut-off values
that were highly predictive of positive OFCs.37 However, given the
variability in skin test extracts, methods and interpretation, and the
selected high-risk populations used in Sporik's and subsequent
studies, the generalizability of these values have to be interpreted
with caution.38 Three decades ago few allergists performed oralfood challenges, whereas today oral food challenges are the
accepted “gold standard”27,39 and efforts have been made to stan-
dardize the procedure worldwide.15
For decades allergists and clinicians have been aware that many
young infants “outgrow” their food allergies, especially to foods
such as milk, egg, soy and wheat, whereas allergies to other foods,
e.g. peanuts, tree nuts and seafood, are more likely to persist
throughout life. However, it was not until the late 1990's when
investigators began mapping allergenic (IgE-binding) epitopes on
food proteins that an immunologic mechanism underlying this
phenomenon became more apparent. These studies showed that
childrenwho outgrew their egg ormilk allergy, i.e. about 80% of this
population, produced IgE antibodies primarily to conformational
(3-dimensional) epitopes whereas those with persistent (lifelong)
allergy also generated signiﬁcant quantities of IgE antibodies to
sequential (linear) epitopes,40,41 suggesting different phenotypes of
IgE-mediated food allergy in children. In contrast, most children
with peanut allergy, who typically do not outgrow their peanut
allergy, i.e. 80%e85%, make large quantities of IgE antibodies to
sequential epitopes. In addition it was shown more recently that
the greater a patient's IgE-binding diversity to allergenic epitopes
on peanut proteins, i.e. the more different allergenic epitopes
Table 1
Classiﬁcation of food allergic reactions.
IgE-mediated Mixed IgE- & non-IgE-mediated Non-IgE mediated (cellular)
Skin
Urticaria
Angioedema
Erythematous morbilliform rash
Flushing
Atopic dermatitis Dermatitis herpetiformis
Contact dermatitis
Respiratory
Allergic rhinoconjunctivitis
Acute bronchospasm
Asthma Food-induced pulmonary hemosiderosis (Heiner's Syndrome)
Gastrointestinal
Oral Allergy Syndrome
Acute gastrointestinal spasm
Eosinophilic esophagitis (EOE)
Eosinophilic gastritis
Eosinophilic gastroenteritis
Food protein-induced entero-colitis syndrome (FPIES)
Food protein-induced procto-colitis syndrome (FPIPS)
Food protein-induced enteropathy syndrome
Celiac disease
Cardiovascular
Dizziness & fainting
Anaphylaxis
Food-associated, exercise-induced anaphylaxis
Miscellaneous
Uterine cramping & contractions
Feeling of “pending doom”
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rience a severe allergic reaction following an accidental
ingestion.42,43
Until relatively recently, it was believed that the best strategy to
promote “outgrowing” food allergies was strict allergen avoidance,
which would prevent “boosting” and sustaining the IgE response,
and the concept of patients with different allergic phenotypes, i.e.
those with different ratios of IgE directed at conformational and
sequential epitopes, was not known.27 The theory at that time
behind adherence to strict elimination diets was based primarily on
retrospective observational studies of children with atopic
dermatitis in which it appeared that children who maintained aTable 2
Symptoms associated with food allergic reactions.
Cutaneous Pruritus
Erythema/Flushing
Urticaria
Angioedema
Ocular Pruritus
Tearing
Conjunctival injection
Periorbital edema
Respiratory
Upper Pruritus
Nasal congestion
Rhinorrhea
Sneezing
Hoarseness
Laryngeal edema
Lower Cough
Wheezing
Dyspnea
Chest tightness/pain
Gastrointestinal Oral pruritus
Oral angioedema (lips, tongue, or palate)
Pharyngeal pruritus/tightness
Colicky abdominal pain
Nausea
Vomiting
Diarrhea
Cardiovascular Tachycardia
Dizziness
Loss of consciousness/fainting
Hypotension
Miscellaneous Metallic taste in mouth
Uterine cramping/contractions
Sense of impending doomstrict elimination diet weremore likely to outgrow their milk or egg
allergy compared to those who had frequent accidental in-
gestions.44 However, this observation was likely confounded by
“reverse causation” since children with persistent food allergy, i.e.
thosewho had IgE to sequential epitopes, would experience allergic
reactions to any form of milk or egg, whereas those likely to
outgrow their allergy, i.e. those who had IgE predominately to
conformational epitopes, would only react to unbaked egg or milk.
In fact, the realization that childrenwho outgrew their milk and egg
allergy made IgE antibodies primarily to conformational epitopes40
led to the hypothesis that these children could safely ingest baked-
milk and egg products in which conformational epitopes were
heat-denatured by high oven temperatures, and subsequent
studies conﬁrmed this hypothesis to be true.45,46 In addition, it was
shown that the addition of baked-milk or egg to the diet of these
children actually accelerated the development of tolerance to all
forms of milk and egg products,47,48 and today baked-milk and egg
OFCs and early introduction of baked-milk and egg products into
the diet of infants with milk or egg allergy has become standard
practice.27
Over 80 years ago Grulee and Sanford reported that exclusive
breast feeding in newborn infants reduced the development of
atopic dermatitis 7-fold compared to infants receiving cow's milk.49
This led to a series of studies in the late 1980's and 1990's
demonstrating the beneﬁt of exclusive breast feeding, use of
extensively hydrolyzed infant formulas and/or avoidance of major
allergenic foods from the mothers' and infants' diets in the pre-
vention of atopic dermatitis and milk allergy.50e53 These studies
supported the hypothesis that delaying the exposure to major food
allergens (milk, egg, peanut and ﬁsh) would allow the infant's
immune system to mature, respond appropriately to food antigens,
and decrease the likelihood of the child developing food allergies.
Murine studies had shown that very early introduction of antigen
to immature mouse pups could lead to sensitization and that by
delaying allergen exposure, their immune system would not
generate antibodies against foreign substances.54 At the time,
however, it was not appreciated how much food allergen was
present in house dust,55e57 and how it is likely that many food-
allergic children are sensitized to food proteins by environmental
exposure to food allergens on irritated/inﬂamed skin, e.g. atopic
dermatitis.58 Consequently, by delaying oral exposure that would
normally induce tolerance to allergenic foods, these atopic infants
are left vulnerable to cutaneous sensitization for a more prolonged
H.A. Sampson / Allergology International 65 (2016) 363e369 367period of time.59 In fact, Lack and his colleagues have shown
conclusively that early oral introduction of peanut into the diet of
high risk infants can dramatically reduce the prevalence of peanut
allergy compared to the standard practice of later introduction.60,61
Whether this ﬁnding is similar for other major food allergens re-
mains to be established.62,63
In the past 35 years, we have witnessed remarkable changes in
our basic understanding of food allergic disorders, which have
elevated food allergy from a collection of case reports largely dis-
counted by investigators and clinicians to a “serious science” with
hundreds of articles published annually in high-impact scientiﬁc
journals. Certain potential pathogenic factors, such as the gut
microbiota,64 were barely discussed three decades ago, whereas
today new technologies have enabled investigators to focus on this
new frontier.65e68 Although the ﬁrst case of oral immunotherapy
was published in 1908, no immunotherapeutic approaches to treat
food allergy were being pursued 35 years ago. In 1998, Patriarca
and colleagues described a protocol used in desensitizing a small
cohort of children with food allergy,69 and noted that “…although
further studies (such as a randomized trial) are needed to reinforce the
conclusions of this paper, oral desensitization may represent an
alternative and safe approach in childrenwith food allergy…,”70 In the
past decade, over twenty studies evaluating the effects of OIT,71e77
as well as other forms of immunotherapy have been publish-
ed,78e80 but due the prevalence of signiﬁcant adverse allergic re-
actions and the risk of inducing eosinophilic esophagitis, most
authorities have agreed that OIT is not yet ready for general use in
the clinic.27,81e83
Future
While tremendous progress has been made in the diagnosis and
management of food allergy, especially in the past decade, the next
decade will undoubtedly witness further advances in our under-
standing of basic underlying immunologic mechanisms associated
with food allergy and the development of tolerance. Recent murine
studies indicate that not only the gastrointestinal tract, but normal
skin is a powerful tolerogenic organ that may be exploited for the
prevention and treatment of food allergy.84e87 A recent double-
blind placebo-controlled study demonstrated that the use of
omalizumab in combination with oral immunotherapy (OIT) to
milk could markedly reduce adverse reactions due to OIT compared
to placebo, signiﬁcantly improving the risk:beneﬁt ratio of this
approach.88 A number of other novel therapies are in pre-clinical or
early clinical trials for treating food allergies: epicutaneous
immunotherapy has shown promise in pre-clinical murine models
and in a phase I and II clinical trial89,90; an herbal formulation based
on traditional Chinese medicine has proved effective in pre-clinical
murine studies and shown some positive responses in early human
trials91e93; and CpG-coated nanoparticles containing food pro-
tein,94 modiﬁed allergenic proteins95,96 and toll-like receptor (TLR)-
conjugated proteins similar to those used for grass pollen immu-
notherapy,97,98 have all shown promise in murine models of food
allergy. A number of trials are now underway to determine the
most effective strategies for preventing food allergies and a number
of diagnostic approaches, e.g. allergenic epitope analysis99 and
basophil activation assays100e102 are being evaluated for their
ability to provide better tools for accurately identifying patients
with symptomatic food allergy.
While the past three decades have witnessed a major expansion
in funding and the number of investigators pursuing food allergy
research, an exponential growth in our knowledge about food al-
lergies and some promising therapeutic approaches that could
become available in the clinic in the next few years, many questions
remain. To move the ﬁeld forward it is essential that we criticallyreassess published studies and retain strict adherence to the sci-
entiﬁc method in future investigation, seek a better understanding
of the basic immunology of “tolerance” and immunopathogenic
mechanisms of food allergy in man, evaluate the structural prop-
erties of food allergens and effects of food processing and additives,
explore the gut and skin microbiome and their effects on immune
tolerance and hypersensitivity, and explore the human genome to
uncover clues as to other mechanisms and pathways not yet
appreciated that may contribute to the development of symptom-
atic food allergies. Despite the great advances in the ﬁeld of food
allergy, the remaining questions will likely keep investigators
occupied for at least the next three decades.Acknowledgement
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